Immunology Investor Event
No effective therapies for severe COPD patients who
failed standard of care
Gold Guidelines
(2018)¹
Group C
Group D
Consider roflumilast
if FEV, 50% pred.
and patient has
chronic bronchitis
Further
exacerbation(s)
LAMA + LABA
Further
exacerbation(s)
LAMA
LABA+ICS
Further
exacerbation(s)
LAMA
Group A
Continue, stop or
try alternative class
of bronchodilator
Group B
LAMA + LABA
evaluate
effect
A bronchodilator
Consider macrolide
-
(in former smokers)
-
LAMA
+ LABA
+ ICS
Persistent
symptoms/further
exacerbation(s)
LAMA + LABA
LABA + ICS
Persistent
symptoms
A long-acting bronchodilator
(LABA or LAMA)
Preferred treatment →→→→
In patients with a major discrepancy between the perceived level of symptoms and severity of airflow limitation, further evaluation is warranted
-
sanofi
Highly symptomatic
frequent exacerbations
Highest mortality
Major driver of
healthcare
costs in COPD
No effective advanced
therapies to date
-
3rd leading cause of death worldwide,
COPD is a progressive disease that
imposes a significant burden
- Typically treated with inhaled steroids
or bronchodilators -"one size fits all"
therapies
DupixentⓇ & itepekimab being studied
for the potential treatment of moderate
to severe COPD patients estimated to
be ~2 million patients²
No biologics treatment approved
No new MoAs in more than 10 yrs
1. Pharmacological treatment algorithms by GOLD Grade. Gold guidelines 2018 2. G7 countries: U.S., Canada, France, Germany, Italy, Japan, UK
2. 1 severe or 2 moderate exacerbations per year
12 Immunology Investor EventView entire presentation